Skip to Content
  • Pfizer Buys Medivation

    I wonder how many people have been holding Medivation shares through the years, all the way through? If you have, you must have forgotten that you owned the stu… Read More
  • 3-Bromopyruvate: What a Mess

    There have been several reports of the use of 3-bromopyruvate as an anticancer therapy, despite (as far as I can see) a lack of any controlled human data. Peopl… Read More
  • A Painful Cancer Advertisement

    There’s an op-ed in the New York Times that makes tough reading, and it’s something that we’re going to be seeing more of. The author, Matt J… Read More
  • Opdivo: Euphoria to Panic

    We’ve gotten used to seeing one success after another in the cancer immunotherapy field, so this morning’s news is a bit of a shock: the Bristol-Mye… Read More
  • CAR-T Deaths Cannot Be Good

    Late yesterday afternoon, Matthew Herper broke the news that Juno Therapeutics had had their CAR-T leukemia trial put on hold after three patient deaths. That&# Read More
  • Can’t Shake Failure Yet

    From the new Endpoints site, here’s a roundup of the worst moments in the clinic for drug development in the first half of 2016. Several of them were cove… Read More
  • PARP Inhibitors Come Through

    PARP (poly ADP-ribose polymerase) inhibitors have had a rough time of it in the clinic. Sanofi had one (iniparib) fail, but it later turned out, embarrassingly… Read More
  • The Immuno-oncology Traffic Jam

    Bruce Booth has a valuable look at the immuno-oncology field here. Everyone knows that it’s a hot area, but the numbers show that it’s even (better… Read More
Page 5 of 38« First...34567...102030...Last »